Abstract: The invention provides an improved method for preparing lysine acetylsalicylate?glycine (LASAG) that allows for high yields without the need for an addition of seed crystal, as well as yielding controlled, small particle sizes (median particles size preferably <40 ?m) and high stability of the LASAG. Advantageously, the method can be performed at room temperature without negatively impacting yield or particle properties. The invention also provides the LASAG obtained from said method, and its uses as a medicine.

Abstract: The invention provides a compound, namely acetylsalicylic acid (ASA) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising ASA or a pharmaceutically acceptable salt thereof, for use in the treatment of a patient, e.g. a human being, suffering from a severe influenza virus infection and/or a symptom or condition associated therewith (namely, nasal congestion, sore throat, cough, fever, fatigue, headache and myalgias), wherein said use comprises the administration of a composition comprising ASA or a pharmaceutically acceptable salt thereof to the patient by inhalation.

Abstract: The invention provides a compound, namely acetylsalicylic acid (ASA) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising ASA or a pharmaceutically acceptable salt thereof, for use in the treatment of a patient, e.g. a human being, suffering from a severe influenza virus infection and/or a symptom or condition associated therewith (namely, nasal congestion, sore throat, cough, fever, fatigue, headache and myalgias), wherein said use comprises the administration of a composition comprising ASA or a pharmaceutically acceptable salt thereof to the patient by inhalation.

Abstract: The invention relates to a method for the production of acetylsalicylic acid lysinate, optionally lysine acetylsalicylate.

Abstract: The invention relates to a method for the production of acetylsalicylic acid lysinate, optionally lysine acetylsalicylate.

Abstract: The invention provides a compound, namely acetylsalicylic acid (ASA) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising ASA or a pharmaceutically acceptable salt thereof, for use in the treatment of a patient, e.g. a human being, suffering from a severe influenza virus infection and/or a symptom or condition associated therewith (namely, nasal congestion, sore throat, cough, fever, fatigue, headache and myalgias), wherein said use comprises the administration of a composition comprising ASA or a pharmaceutically acceptable salt thereof to the patient by inhalation.